The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses.

David Fisman, Norberto Giglio, Myron J Levin, Van Hung Nguyen, Stephen I Pelton, Maarten Postma, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F Mould-Quevedo

Human vaccines & immunotherapeutics 2024 Dec 31

filter terms:

Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.

Citation

David Fisman, Norberto Giglio, Myron J Levin, Van Hung Nguyen, Stephen I Pelton, Maarten Postma, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F Mould-Quevedo. The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses. Human vaccines & immunotherapeutics. 2024 Dec 31;20(1):2351675